Market revenue in 2023 | USD 72.8 million |
Market revenue in 2030 | USD 117.0 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.46% in 2023. Horizon Databook has segmented the Spain central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
Spain holds a vast potential for growth in central lab market due to the high volume of clinical trials conducted in the country. The Spanish Agency of Medicines and Medical Devices “AEMPS” approved over 1,019 trials in 2020, a majority of which were aimed at investigating treatment options for cancer and COVID-19.
The strength of the country’s healthcare system lies in the availability of highly qualified professionals and strong presence of pharmaceutical companies, which is anticipated to drive the adoption of clinical trials.
In addition, the country is expected to benefit from the new Clinical Trials Information System launched in January 2022, which enables centralization of processes for accelerating the pace of clinical studies.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain central lab market , including forecasts for subscribers. This country databook contains high-level insights into Spain central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account